

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF THE  
04 AUG 20 AM

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Hoffmann-La Roche Inc.*			
2. Address <input checked="" type="checkbox"/> Check if different than previously reported 1425 K Street NW, Suite 650, Washington, DC 20005			
3. Principal Place of Business (if different from line 2) Nutley NJ/07110 City: State/zip (or Country)			
4. Contact Name Candace Sams	Telephone (202) 408-0090	E-mail (optional) candace.sams@roche.com	5. Senate ID # 18411-12
7. Client Name <input checked="" type="checkbox"/> Self Self			6. House ID # 31167000

**TYPE OF REPORT** 8. Year 2004 Midyear (January 1-June 30) ☒ OR Year End (July 1-Dec

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ ⇨ Termination Date \_\_\_\_\_

11. No Lobbying

### INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p><b>12. Lobbying Firms</b></p> <p><b>INCOME</b> relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p><b>13. Organizations</b></p> <p><b>EXPENSES</b> relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u>\$1,657,669</u> Expenses (nearest \$20,000)</p> <p><b>14. REPORTING METHOD.</b> Check box to indicate accounting method. See instructions for description of</p> <p><input type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definition</p> <p><input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6033 Internal Revenue Code</p> <p><input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162(e) Internal Revenue Code</p>
---	--

\*This registration also covers the affiliates of the Registrant

the parent company, F. Hoffmann-La Roche Ltd.  
Signature Michael J. Eging Date 8/11/04  
Printed Name and Title Michael J. Eging, Exec. Dir., Federal Govt. Affairs/Public Policy

LD-2 (REV 4/03)

PAGE 1 of

Registrant Name Hoffmann-La Roche Inc. Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which t engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each c information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

S. 812--Greater Access to Affordable Pharmaceuticals Act of 2001


17. House(s) of Congress and Federal agencies contacted ☐ Check if None

United States House of Representatives  
United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Michael Eging	Executive Director, Federal Government Affairs
Kelli Mills	Assistant Director, Federal Government Affairs
David Nichols	Director, Federal Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Signature  Date 01/11/01  
Printed Name and Title Michael J. Eging, Exec. Dir., Federal Govt. Affairs/Public Policy

Form LD-2 (Rec. 4/03)

Page 3

Registrant Name Hoffmann-La Roche Inc. Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which t engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each c information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

S. 1931, Amend Title XVIII of Social Security Act to Improve Patient Access to and Utilization of Colorectal Cancer Screening Benefit Under Medicare Program.  
S.193, Access to Cancer Therapies Act.  
S.847, Early Treatment for HIV Act of 2003  
S.1143, Hepatitis C Epidemic Control and Prevention Act

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

United States House of Representatives  
United States Senate  
Department of Health and Human Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Michael Eging	Executive Director, Federal Government Affairs
Kelli Mills	Assistant Director, Federal Government Affairs
David Nichols	Director, Federal Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Signature Michael J. Eging Date 2/11/01

Printed Name and Title Michael J. Eging, Exec. Dir., Federal Govt. Affairs/Public Policy

Form LD-2 (Rec. 4/03)

Page 4

Registrant Name Hoffmann-La Roche Inc. Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

S.2729, Amend Title XVII of Social Security Act to provide for a Medicare voluntary prescription drug delivery program.  
S.2766, Making Appropriations for the Departments of Labor, HHS & Education.  
S.987, To Amend Title XIX of Social Security Act to Permit States the Option to Provide Medicaid Coverage for HIV.  
S.1976, Provide for a Comprehensive Federal Effort Relating to Treatments for and Prevention of Cancer.  
S.710, To Require Coverage for Colorectal Cancer Screenings.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

United States House of Representatives  
United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Michael Eging	Executive Director, Federal Government Affairs
Kelli Mills	Assistant Director, Federal Government Affairs
David Nichols	Director, Federal Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Signature Michael J. Eging Date 8/11/07

Printed Name and Title Michael J. Eging, Exec. Dir., Federal Govt. Affairs/Public Policy



Registrant Name Hoffmann-La Roche Inc. Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which t engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each c information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

Lobbied to support increases in the FY 2004 Labor/Health and Human Services/Education Appropriations bill for enhanced access to HIV therapies under the Ryan White CARE Act.

Lobbied to support VA Standardization of Glucose Testing equipment

Lobbied to support Veterans Administration HUD Appropriations Bill

Lobbied to support BSE Test Approval

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

United States House of Representatives  
United States Senate  
Veterans Administration  
U.S. Department of Agriculture

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Michael Eging	Executive Director, Federal Government Affairs
Kelli Mills	Assistant Director, Federal Government Affairs
David Nichols	Director, Federal Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Signature Michael J. Eging Date 0/11/07

Printed Name and Title Michael J. Eging, Exec. Dir., Federal Govt. Affairs/Public Policy

Form LD-2 (Rev. 4/03)

Page 6

Registrant Name Hoffmann-La Roche Inc. Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

HR 1641, Medicaid Obesity Treatment Act  
S.2625, Amend Title XVIII of Social Security Act to Provide Coverage of Outpatient Prescription Drugs under the Medicare Program  
HR 4860, Amend Title XVIII of Social Security Act to Provide for Voluntary Program for Prescription Drug Coverage Under Medicare.  
HR 1839, Immunosuppressive Drug Coverage Act

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

United States House of Representatives  
United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Michael Eging	Executive Director, Federal Government Affairs
Kelli Mills	Assistant Director, Federal Government Affairs
David Nichols	Director, Federal Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Signature Michael J. Eging Date 8/11/04

Printed Name and Title Michael J. Eging, Exec. Dir., Federal Govt. Affairs/Public Policy

Form LD-2 (Rec. 4/03)

Page 7

Registrant Name Hoffmann-La Roche Inc. Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code and provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

S. 880, Immunosuppressive Drug Coverage Act  
 HR 3032, Medicare Coverage of Immunosuppressives Drug Coverage  
 S. 1204, Comprehensive Immunosuppressive Drug Coverage Act  
 S.358, Medicare Prescription Drug and Modernization Act


17. House(s) of Congress and Federal agencies contacted ☐ Check if None

United States House of Representatives  
 United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Michael Eging	Executive Director, Federal Government Affairs
Kelli Mills	Assistant Director, Federal Government Affairs
David Nichols	Director, Federal Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Signature  Date 8/11/07

Printed Name and Title Michael J. Eging, Exec. Dir., Federal Govt. Affairs/Public Policy

Form LD-2 (Rec. 4/03)

Page 8

Registrant Name Hoffmann-La Roche Inc. Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which t engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each c information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific lobbying issues

HR 5029--Taxation/Internal Revenue Code

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

United States House of Representatives  
United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Michael J. Eging	Executive Director, Federal Government Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Signature Michael J. Eging Date 5/11/01

Printed Name and Title Michael J. Eging, Exec. Dir., Federal Govt. Affairs/Public Policy

Form LD-2 (Rec. 4/03)

Page 9



Registrant Name Hoffmann-La Roche Inc. Client Name Self

**Information Update Page - Complete ONLY where registration information has changed.**

20. Client new address

As on page 1, this report covers affiliates of the Registrant and F. Hoffmann-La Roche Ltd

21. Client new principal place of business (if different from line 20)

City Basel

State/Zip (or Country) Switzerland

22. New general description of client's business or activities

**LOBBYIST UPDATE**

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

**ISSUE UPDATE**

24. General lobbying issues previously reported that **no longer** pertain

**AFFILIATED ORGANIZATIONS**

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)


26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

**FOREIGN ENTITIES**

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities

28. Name of each previously reported foreign entity that **no longer** owns, or controls, or is affiliated with the registrant, or affiliated organization

Signature  Date 01/11/07

Printed Name and Title Michael Eging, Exec. Dir., Federal Govt. Affairs/Public Policy

Form LD-2 (Rev. 4/03)

Page 10